ClinicalTrials.gg
CompletedNCT00737048Updated Mar 31, 2016Results posted

A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

A Phase 3 interventional study of Tramadol Hydrochloride and Acetaminophen in Pain and Postoperative Pain, sponsored by Janssen Pharmaceutical K.K.. Completed at 12 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-03-31.

Primary conditionPain, PostoperativeRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain, Postoperative
Why
  1. The study's listed conditions name Pain, Postoperative, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies testing tramadol in Pain, Postoperative — 3 open to participants now, 5 under way, none of them phase 3. Tramadol · Pain, Postoperative.

Enrollment
6th of 34
328 · median 93
Started
2008
the only one that year
Phase 3
3 of 34
none open now
Registered
3rd of 34
by date

Among the 34 studies testing tramadol in Pain, Postoperative, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 3, and was the 3rd registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 34 studies testing tramadol in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing tramadol in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of JNS013 with single oral dose administration in participants with pain after tooth-extraction of mandibular impacted wisdom tooth.

Read the detailed description

This is a multi-center (conducted in more than one center), double-blind (neither Physician nor participant knows the name of the assigned drug), randomized (study drug assigned by chance), parallel-group (each group of participant will be treated at the same time) and comparative study in participants having pain intensity of at least 50.0 millimeter (mm) (on visual analog scale, score ranging from 0 mm [no pain] to 100 mm [worst possible pain]), following extraction of an impacted mandibular wisdom tooth. The study consists of 3 parts: Pre-observation (7 days before study commences on Day 1); Treatment (Day 1, consists of single oral dosing of either tramadol plus acetaminophen and placebo; or tramadol and placebo; or acetaminophen and placebo) and Follow-up (Day 2 and 8). All the eligible participants will be randomly assigned to 1 of the 3 study treatments. Efficacy of the participants will primarily be evaluated through total pain relief, which will be evaluated on numerical rating scale. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Pain
  • Postoperative Pain

Browse trials for

Keywords

  • Pain
  • Tooth extraction
  • Oral surgery
  • Postoperative pain
  • JNS013
  • Tramadol hydrochloride
  • Acetaminophen
04

In context

Pain, Postoperative Reclassified

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

This study's enrollment of 328 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.

Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants planned to receive a tooth extraction of one mandibular impacted wisdom tooth
  • Participants who require bone removal and separation of the crown at tooth extraction
  • Participants whose intensity of pain associated with tooth extraction within 2 hours after tooth extraction is greater than or equal to 50.0 millimeter on the visual analog scale (VAS)
  • Participants who did not undergo general anesthesia or sedation at tooth extraction
  • Participants without an abnormality (including laboratory test values) corresponding to Grade 3 in the "Criteria for severity classification of adverse drug reactions" during the pretreatment observation period

Exclusion criteria

Exclusion Criteria:

  • Participants with conditions for which tramadol is
  • Participants with conditions for which acetaminophen is contraindicated
  • Participants with history of convulsions or the possibility of convulsive seizures
  • Pregnant participants or those who may be pregnant, lactating mothers, and those who wish pregnancy during the study period
  • Participants with concurrent, previous, or possible alcohol dependence, drug dependence or narcotic addiction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    Tramadol plus Acetaminophen and Placebo

    Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (\>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).

    Drug: Placebo · Drug: Tramadol plus Acetaminophen

  • Experimental
    Tramadol and Placebo

    Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).

    Drug: Tramadol Hydrochloride · Drug: Placebo

  • Experimental
    Acetaminophen and Placebo

    Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).

    Drug: Acetaminophen · Drug: Placebo

Interventions

  • Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).

  • Acetaminophen two oral capsules will be administered once as 650 mg.

  • DrugPlacebo

    Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.

  • DrugTramadol plus Acetaminophen

    Drug pages: Tramadol · Acetaminophen

    Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.

    Also known as: JNS013

07

What researchers measure

Primary outcomes

  1. Total Pain Relief Based on Numerical Rating Scale (NRS) Score

    Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.

    Time frame: 8 hours

Secondary outcomes

  1. Total Pain Relief Based on Numerical Rating Scale (NRS) Score Every 4 Hours up to 8 Hours

    Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.

    Time frame: Baseline up to 8 hours post-administration of study treatment

  2. Sum of Pain Intensity Difference (SPID)

    Pain Intensity (PI) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and 8 hours post-administration of study treatments.Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).

    Time frame: Baseline up to 8 hours post-administration of study treatment

  3. Sum of Pain Relief Combined With Pain Intensity Difference (SPRID)

    The SPRID is the sum of pain relief scores combined with pain intensity difference, score ranging from from (-) 24 (the worst) through 56 (the most improved). Higher score indicates treatment response. Pain Intensity (PI) and Pain relief (PAR) were assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and at 8 hours post-administration of study treatments. Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).

    Time frame: Baseline up to 8 hours post-administration of study treatment

  4. Change From Baseline in Visual Analog Scale (VAS) Score at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment

    Pain was assessed by using Visual Analogue Scale (VAS) score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented treatment response.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment

  5. Mean Change Over Time for Pain Intensity Difference (PID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-Administration of Study Treatment

    The PID is defined as difference between current pain intensity (PI) and Baseline PI, PI was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment

  6. Mean Change Over Time for Pain Relief (PAR) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment

    Pain Relief (PAR) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment

  7. Mean Change Over Time for Pain Relief Combined With Pain Intensity Difference (PRID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment

    Pain Relief combined with pain Intensity Difference (PRID) represented pain relief scores combined with Pain Intensity difference (PID) scores. PRID score ranges from -3 (the worst) through +7 (the most improved). Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment

  8. Time to Reach the Onset of Drug Efficacy and Time to Recurrence of Pain After the Onset of Drug Efficacy

    Time to reach the onset of drug efficacy (TOE) means time took by participants for the onset of relief from pain after tooth-extraction and time to recurrence of pain (TOR) after the onset of drug efficacy (that is, duration of drug efficacy) were assessed after study drug treatment.

    Time frame: Baseline up to 8 hours post-administration of study treatment

  9. Percentage of Participants With Categorical Score for Patient Impressions

    Percentage of participants with patient impressions were assessed on categories, that are: worked well; worked; worked a little; and didn't work.

    Time frame: Baseline up to 8 hours post-administration of study treatment

  10. Number of Participants Treated With a Relief Analgesic

    Participants who were treated with a relief analgesic were assessed. Analgesics are the compounds capable of relieving pain without the loss of consciousness.

    Time frame: Baseline up to 8 hours post-administration of study treatment

  11. Percentage of Participants With Treatment Response Based on Evaluation Criteria for Efficacy of Analgesics in Post-Tooth-Extraction Pain

    Percentage of participants were assessed with treatment response based on "evaluation criteria for efficacy of analgesics in post-tooth-extraction pain" for the efficacy of analgesics used to treat pain following tooth extraction. Participants were assessed as "very effective, effective, somewhat effective and ineffective" for the following categories: Pain suppression (PS), speed of pain relief (SPR), duration of pain relief (DPR), general effectiveness (GE). Participants judged the treatment as "extremely useful, useful, not useful \& could not be assessed" for overall evaluation (OE).

    Time frame: Baseline up to 8 hours post-administration of study treatment

08

Results

Posted Aug 1, 2013

Participant flow

Participant flow — Overall Study
MilestoneTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Started13266130
Completed12960126
Not completed364
Withdrew: Physician decision001
Withdrew: Adverse event010
Withdrew: Worsening of the symptoms353

Outcome measures

PrimaryTotal Pain Relief Based on Numerical Rating Scale (NRS) Score

Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.

Time frame:
8 hours
Reported as:
Mean · Units on a scale
Total Pain Relief Based on Numerical Rating Scale (NRS) Score
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Total Pain Relief Based on Numerical Rating Scale (NRS) Score17.7 ± 7.9112.4 ± 8.3613.3 ± 8.07
Statistical analysis
  • Tramadol Hydrochloride Plus Acetaminophen and Placebo vs Tramadol Hydrochloride and Placebo · Fisher Least Significant Difference Method · p = <0.0001 · Mean difference (final values): -5.3
  • Tramadol Hydrochloride Plus Acetaminophen and Placebo vs Acetaminophen and Placebo · Fisher Least Significant Difference Method · p = <0.0001 · Mean difference (final values): -4.3
SecondaryTotal Pain Relief Based on Numerical Rating Scale (NRS) Score Every 4 Hours up to 8 Hours

Total pain relief was evaluated using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response.

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Total Pain Relief Based on Numerical Rating Scale (NRS) Score Every 4 Hours up to 8 Hours
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
0-4 hours9.6 ± 3.906.3 ± 4.117.4 ± 3.97
4-8 hours8.0 ± 4.736.1 ± 4.675.9 ± 4.71
SecondarySum of Pain Intensity Difference (SPID)

Pain Intensity (PI) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and 8 hours post-administration of study treatments.Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Sum of Pain Intensity Difference (SPID)
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Sum of Pain Intensity Difference (SPID)6.4 ± 5.902.9 ± 5.124.1 ± 5.84
SecondarySum of Pain Relief Combined With Pain Intensity Difference (SPRID)

The SPRID is the sum of pain relief scores combined with pain intensity difference, score ranging from from (-) 24 (the worst) through 56 (the most improved). Higher score indicates treatment response. Pain Intensity (PI) and Pain relief (PAR) were assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Scores were measured at Baseline (that is, 0 hours after tooth extraction) and at 8 hours post-administration of study treatments. Pain intensity difference (PID) was calculated (that is, for 0-8 hours, time point \[8 hour\] score minus baseline \[0 hour\] score).

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Sum of Pain Relief Combined With Pain Intensity Difference (SPRID)
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Sum of Pain Relief Combined With Pain Intensity Difference (SPRID)24.0 ± 13.0315.3 ± 12.4317.4 ± 13.17
SecondaryChange From Baseline in Visual Analog Scale (VAS) Score at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment

Pain was assessed by using Visual Analogue Scale (VAS) score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented treatment response.

Time frame:
0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Change From Baseline in Visual Analog Scale (VAS) Score at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Change at Hour 0.5-22.11 ± 23.466-4.28 ± 20.001-15.50 ± 22.336
Change at Hour 1-36.79 ± 23.603-12.82 ± 27.372-26.68 ± 24.570
Change at Hour 2-42.71 ± 23.631-20.94 ± 27.904-28.43 ± 27.583
Change at Hour 3-41.40 ± 26.707-25.75 ± 28.509-28.40 ± 30.544
Change at Hour 4-37.70 ± 27.266-21.75 ± 29.870-24.83 ± 30.753
Change at Hour 5-34.78 ± 28.173-17.56 ± 29.110-21.48 ± 31.350
Change at Hour 6-30.20 ± 30.932-15.70 ± 31.033-17.51 ± 31.875
Change at Hour 7-26.37 ± 32.456-13.18 ± 30.335-15.62 ± 32.562
Change at Hour 8-22.85 ± 33.116-13.03 ± 30.916-14.48 ± 32.638
SecondaryMean Change Over Time for Pain Intensity Difference (PID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-Administration of Study Treatment

The PID is defined as difference between current pain intensity (PI) and Baseline PI, PI was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.

Time frame:
0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Mean Change Over Time for Pain Intensity Difference (PID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-Administration of Study Treatment
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
PID:Change at Hour 0.50.6 ± 0.670.1 ± 0.550.5 ± 0.73
PID:Change at Hour 10.9 ± 0.710.4 ± 0.700.7 ± 0.72
PID:Change at Hour 21.1 ± 0.780.5 ± 0.710.8 ± 0.79
PID:Change at Hour 31.1 ± 0.870.5 ± 0.730.7 ± 0.84
PID:Change at Hour 40.9 ± 0.850.4 ± 0.700.6 ± 0.84
PID:Change at Hour 50.8 ± 0.850.3 ± 0.730.5 ± 0.88
PID:Change at Hour 60.7 ± 0.880.4 ± 0.800.4 ± 0.88
PID:Change at Hour 70.6 ± 0.920.2 ± 0.770.3 ± 0.93
PID:Change at Hour 80.5 ± 0.940.2 ± 0.770.3 ± 0.91
SecondaryMean Change Over Time for Pain Relief (PAR) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment

Pain Relief (PAR) was assessed using numerical rating scale score ranging from 0 to 32, wherein 0 indicates no treatment response and 32 indicates the most improved. Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.

Time frame:
0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Mean Change Over Time for Pain Relief (PAR) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
PAR:Change at Hour 0.51.5 ± 1.120.7 ± 0.861.3 ± 0.99
PAR:Change at Hour 12.3 ± 1.081.4 ± 1.132.0 ± 1.11
PAR:Change at Hour 22.7 ± 1.061.7 ± 1.232.0 ± 1.18
PAR:Change at Hour 32.6 ± 1.181.9 ± 1.202.0 ± 1.21
PAR:Change at Hour 42.4 ± 1.221.7 ± 1.181.8 ± 1.20
PAR:Change at Hour 52.2 ± 1.211.6 ± 1.161.6 ± 1.27
PAR:Change at Hour 62.1 ± 1.201.6 ± 1.281.5 ± 1.25
PAR:Change at Hour 71.9 ± 1.301.5 ± 1.191.4 ± 1.27
PAR:Change at Hour 81.8 ± 1.301.5 ± 1.151.4 ± 1.25
SecondaryMean Change Over Time for Pain Relief Combined With Pain Intensity Difference (PRID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment

Pain Relief combined with pain Intensity Difference (PRID) represented pain relief scores combined with Pain Intensity difference (PID) scores. PRID score ranges from -3 (the worst) through +7 (the most improved). Higher score indicates treatment response. Mean change from Baseline (that is, 0 hours after tooth extraction) at specified end time points were evaluated.

Time frame:
0.5, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-administration of study treatment
Reported as:
Mean · Units on a scale
Mean Change Over Time for Pain Relief Combined With Pain Intensity Difference (PRID) at 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 Hours Post-administration of Study Treatment
Units on a scaleTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
PRID:Change at Hour 0.52.1 ± 1.670.8 ± 1.291.8 ± 1.61
PRID:Change at Hour 13.2 ± 1.681.8 ± 1.712.7 ± 1.69
PRID:Change at Hour 23.8 ± 1.712.2 ± 1.802.8 ± 1.85
PRID:Change at Hour 33.7 ± 1.922.4 ± 1.752.7 ± 1.92
PRID:Change at Hour 43.3 ± 1.952.1 ± 1.712.4 ± 1.92
PRID:Change at Hour 53.0 ± 1.931.9 ± 1.742.1 ± 2.03
PRID:Change at Hour 62.8 ± 1.961.9 ± 1.921.8 ± 2.00
PRID:Change at Hour 72.5 ± 2.121.7 ± 1.811.8 ± 2.08
PRID:Change at Hour 82.3 ± 2.121.7 ± 1.781.6 ± 2.04
SecondaryTime to Reach the Onset of Drug Efficacy and Time to Recurrence of Pain After the Onset of Drug Efficacy

Time to reach the onset of drug efficacy (TOE) means time took by participants for the onset of relief from pain after tooth-extraction and time to recurrence of pain (TOR) after the onset of drug efficacy (that is, duration of drug efficacy) were assessed after study drug treatment.

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Mean · Minutes
Time to Reach the Onset of Drug Efficacy and Time to Recurrence of Pain After the Onset of Drug Efficacy
MinutesTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
TOE (n=102, 36, 104)47.6 ± 40.8882.8 ± 82.8853.5 ± 47.97
TOR (n=41, 14, 53)252.5 ± 119.03207.9 ± 126.44198.2 ± 120.24
SecondaryPercentage of Participants With Categorical Score for Patient Impressions

Percentage of participants with patient impressions were assessed on categories, that are: worked well; worked; worked a little; and didn't work.

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With Categorical Score for Patient Impressions
Percentage of participantsTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Worked well28.7 ± 1016.4 ± 12.4315.7 ± 13.17
Worked55.8 ± 6.2944.3 ± 6.0453.5 ± 6.39
Worked a little13.2 ± 7.7324.6 ± 7.0422.8 ± 7.69
Didn't work2.314.87.9
SecondaryNumber of Participants Treated With a Relief Analgesic

Participants who were treated with a relief analgesic were assessed. Analgesics are the compounds capable of relieving pain without the loss of consciousness.

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Number · Participants
Number of Participants Treated With a Relief Analgesic
ParticipantsTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Number of Participants Treated With a Relief Analgesic372554
SecondaryPercentage of Participants With Treatment Response Based on Evaluation Criteria for Efficacy of Analgesics in Post-Tooth-Extraction Pain

Percentage of participants were assessed with treatment response based on "evaluation criteria for efficacy of analgesics in post-tooth-extraction pain" for the efficacy of analgesics used to treat pain following tooth extraction. Participants were assessed as "very effective, effective, somewhat effective and ineffective" for the following categories: Pain suppression (PS), speed of pain relief (SPR), duration of pain relief (DPR), general effectiveness (GE). Participants judged the treatment as "extremely useful, useful, not useful \& could not be assessed" for overall evaluation (OE).

Time frame:
Baseline up to 8 hours post-administration of study treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Response Based on Evaluation Criteria for Efficacy of Analgesics in Post-Tooth-Extraction Pain
Percentage of participantsTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
PS:very effective (n=107, 46, 113)19.48.29.6
PS:effective (n=107, 46, 113)2.800
PS:somewhat effective (n=107, 46, 113)63.942.967.5
PS:ineffective (n=107, 46, 113)13.949.022.8
SPR:very effective (n=107, 46, 113)56.921.644.8
SPR:effective (n=107, 46, 113)26.621.628.4
SPR:somewhat effective (n=107, 46, 113)7.315.710.3
SPR:ineffective (n=107, 46, 113)9.241.216.4
DPR:very effective (n=41, 14, 53)39.028.624.5
DPR:effective (n=41, 14, 53)26.835.728.3
DPR:somewhat effective (n=41, 14, 53)17.17.120.8
DPR:ineffective (n=41, 14, 53)17.128.626.4
GE:very effective (n=107, 46, 113)2.800
GE:effective (n=107, 46, 113)33.913.723.3
GE:somewhat effective (n=107, 46, 113)46.831.453.4
GE:ineffective (n=107, 46, 113)16.554.923.3
OE:Extremely useful (n=107, 46, 113)0.900
OE:useful (n=107, 46, 113)11.93.917.2
OE:not useful (n=107, 46, 113)87.296.182.8
OE:could not be assessed (n=107, 46, 113)000

Adverse events

Collected over Baseline up to Day 8. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol Hydrochloride Plus Acetaminophen and Placebo—0/132 (0%)82/132 (62.1%)
Tramadol Hydrochloride and Placebo—0/66 (0%)40/66 (60.6%)
Acetaminophen and Placebo—1/130 (0.8%)52/130 (40%)
Most frequent serious events
Most frequent serious events
EventTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
Drug hypersensitivityImmune system disorders0/1320/661/130
Most frequent other events
Showing 10 of 50
Most frequent other events
EventTramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and Placebo
SomnolenceNervous system disorders39/13215/6614/130
NauseaGastrointestinal disorders20/13210/664/130
DizzinessNervous system disorders12/1325/660/130
Blood bilirubin increasedInvestigations12/1326/6611/130
Alveolar osteitisInfections and infestations6/1321/6610/130
HeadacheNervous system disorders7/1325/664/130
VomitingGastrointestinal disorders10/1322/661/130
Feeling abnormalGeneral disorders4/1325/661/130
DiarrhoeaGastrointestinal disorders1/1320/664/130
Stomach discomfortGastrointestinal disorders4/1320/660/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and PlaceboTotal
Mean28.1 ± 8.327.8 ± 8.627.5 ± 8.227.8 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Tramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and PlaceboTotal
Female613266159
Male713464169
Visual Analog Scale (VAS) Score
Visual Analog Scale (VAS) Score(Units on a scale)Tramadol Hydrochloride Plus Acetaminophen and PlaceboTramadol Hydrochloride and PlaceboAcetaminophen and PlaceboTotal
Mean62.28 ± 9.8560.33 ± 7.6361.32 ± 8.8161.51 ± 9.04
09

Study locations

12 sites
  • Isehara, Japan
  • Kitakyushu, Japan
  • Kumamoto, Japan
  • Ohta-Ku, Japan
  • Osaka, Japan
  • Sapporo, Japan
  • Shimotsuga, Japan
  • Shimotsuke, Japan
  • Tokyo, Japan
  • Yokohama N/A, Japan
  • Yokohama, Japan
  • Yokosuka, Japan
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2008
First posted
Aug 18, 2008
Start
Mar 2008
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Aug 1, 2013
Last update
Mar 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00737048
Responsible party
Sponsor
First posted
Aug 18, 2008
Start date
Mar 2008
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Aug 1, 2013
Last update
Mar 31, 2016

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion